Clinical trials: Very High Risk Prostate Carcinoma
Prostate Cancer, Prostate Adenocarcinoma
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy…
- Trial name
- Prostate005 (NCT04465500)
- Testing
- External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Prostate Cancer
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Darolutamide combined with Androgen-Deprivation Therapy in High-risk/Very high-risk localized prostate cancer.
- Trial name
- NCT05249712
- Testing
- Darolutamide 300 mg, Androgen deprivation therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer
This phase I trial tests the safety and feasibility of giving pasritamig before surgery in patients with unfavorable intermediate-risk, high-risk, or very high-risk localized prostate cancer.
- Trial name
- NCT07860255
- Testing
- Pasritamig
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
This study assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
- Trial name
- NCT06122584
- Testing
- [18F]PSMA-1007
- Where
- 18 sites in France, Germany and 4 more
- Volunteers
- 380 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
This phase III/IV trial compares the impact of leuprolide and abiraterone acetate (AA) versus relugolix and AA on the heart in hormone-naive patients with advanced prostate cancer receiving pelvic radiation therapy.
- Conditions
- Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT06650579
- Testing
- Abiraterone Acetate, Bicalutamide, Biospecimen Collection
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Emory University
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
This randomized, controlled, single center clinical trial aims to evaluate the efficacy and safety of Androgen Deprivation Therapy Combined with Docetaxel for High Risk Prostate Cancer with a six-month treatment cycle.
- Trial name
- NCT04869371
- Testing
- Docetaxel injection, Triptorelin Pamoate for Injectable Suspension, Prednisone Acetate Tablets
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Hongqian Guo
Prostate Cancer
AASUR in High Risk Prostate Cancer
The purpose of this study is to determine whether anti-testosterone medications, when administered before, during, and after high-dose, precision radiation, will be effective in preventing the prostate cancer from returning.
- Trial name
- NCT02772588
- Testing
- ARN-509, Abiraterone, Leuprolide
- Where
- 11 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center